Online citations, reference lists, and bibliographies.
← Back to Search

Low Homozygous/high Heterozygous Deletion Status By P16 FISH Correlates With A Better Prognostic Group Than High Homozygous Deletion Status In Malignant Pleural Mesothelioma.

M. Hamasaki, S. Matsumoto, Sousei Abe, D. Hamatake, Toshiaki Kamei, K. Hiroshima, K. Kawahara, A. Sato, T. Tsujimura, Y. Nakatani, Yasuhiro Yoshida, A. Iwasaki, K. Nabeshima
Published 2016 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES Homozygous deletion (homo-d) of the p16 (CDKN2A) gene, as determined by fluorescence in situ hybridization (FISH), helps differentiate malignant pleural mesothelioma (MPM) from reactive mesothelial hyperplasia (RMH). Heterozygous deletion (hetero-d) has also been identified variably in p16 FISH. This study aimed to investigate the significance of homo-d and hetero-d of p16 in the diagnosis and prognosis of MPM. MATERIALS AND METHODS p16 FISH was performed in 93 MPMs and 47 RMHs. Real-time polymerase chain reaction (PCR) and methylation specific PCR (MSP) were also performed for cases in which DNA was available. Overall survival (OS) was assessed via the Kaplan-Meier method and logrank test. RESULTS Cutoff values for homo-d and hetero-d were set at 10% and 47%, respectively, based on p16 FISH results in RMH. In MPM, 80/93 (86.0%) were homo-d positive, and 15/93 (16.1%) were hetero-d positive. No RMH was homo/hetero-d positive. In nine cases of MPM with the low homo-d (<30%)/high hetero-d (>47%) pattern, FISH with a shorter probe caused a slight increase (from 20.1% to 26.5%) in the mean percentage of homo-d and a decrease in that of hetero-d (from 59.6% to 55.6%). Four cases in which the low homo-d/high hetero-d pattern was maintained with the shorter probe were further analyzed by real-time PCR, which separated them into a two (n=2) or one allele deletion group (n=2). MSP revealed no promoter methylation in the two cases with one allele deletion. The OS was significantly shorter in homo-d positive cases (n=24) than homo-d negative cases (n=5, p=0.0002) in the 29 MPM cases with follow-up data. Also, low homo-d/high hetero-d cases (n=5) had a significantly better prognosis than high homo-d (≥30%) cases (n=17, p=0.011). CONCLUSIONS Within p16 homo-d positive MPMs with poorer prognosis, the low homo-d/high hetero-d pattern may belong to a better prognostic subgroup in homo-d positive MPMs.
This paper references
10.1002/cncr.23413
9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA‐ICM, and AgNOR analysis
F. Onofre (2008)
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
J. Cheng (1994)
10.1073/PNAS.93.18.9821
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
J. Herman (1996)
10.1016/J.CANLET.2005.08.010
Molecular pathways in malignant pleural mesothelioma.
B. Whitson (2006)
10.1017/erm.2012.6
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
10.1074/jbc.M110.100354
Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma*
S. Ivanov (2010)
10.1002/cncr.10923
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)
10.1309/AJCPT94JVWIHBKRD
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
10.1002/cncy.21269
Morphology of 9p21 homozygous deletion‐positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology
S. Matsumoto (2013)
10.1378/chest.09-1951
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
S. Savic (2010)
10.1136/jcp.2010.076794
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
C. Chung (2010)
Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma
小林 成行 (2008)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/S0194-5998(96)80594-8
11:40 AM: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization
J. Califano (1996)
10.1007/s00428-008-0689-3
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
10.1016/S0002-9440(10)64734-7
Inverted sinonasal papilloma : a molecular genetic appraisal of its putative status as a Precursor to squamous cell carcinoma.
J. Califano (2000)
10.1111/j.1349-7006.2011.02180.x
Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma
M. Fujii (2012)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
WHO classification of tumours of the lung, pleura, thymus and heart
W. Travis (2015)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1309/AJCPP5R2ZJZKCLWN
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
S. Monaco (2011)
10.1093/carcin/bgt166
Molecular pathogenesis of malignant mesothelioma.
Y. Sekido (2013)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1111/j.1440-1827.2010.02534.x
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis
M. Takeda (2010)
10.1038/modpathol.2009.186
CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
A. Krasinskas (2010)
10.1111/j.1349-7006.2010.01827.x
Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma
A. Sato (2011)
Molecular pathogenesis of malignant mesothelioma, Carcinogenesis
Y. Sekido (2013)
Deletion of chromosomes 13 q and 14 q is a common feature of tumors with BRCA 2 mutations
G. Banneau Rouault (2012)
10.1158/1078-0432.CCR-04-1884
P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma
A. Borczuk (2005)
10.1016/S0194-5998(96)80631-0
Poster 7: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization
J. Califano (1996)
10.1111/j.1440-1843.2005.00694.x
Pathogenesis of malignant pleural mesothelioma
M. Jaurand (2005)
10.1371/journal.pone.0052079
Deletion of Chromosomes 13q and 14q Is a Common Feature of Tumors with BRCA2 Mutations
Audrey Rouault (2012)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)



This paper is referenced by
SIGNIFICANCE OF AGNOR STAINING IN DETERMINING MALIGNANT OR BENIGN PLEURAL EFFUSIONS
Humaira Atta Ullah (2018)
10.18632/oncotarget.22817
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma
Marieke Hylebos (2017)
10.1002/dc.24475
HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
K. Hiroshima (2020)
10.21037/tlcr.2019.11.29
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
D. Chapel (2020)
10.1016/J.PNEUMO.2018.06.004
Le profil anatomoclinique du mésothéliome pleural malin : une étude rétrospective à propos de 30 cas
M. Mlika (2018)
10.1111/pin.12973
Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
Yoshiaki Kinoshita (2020)
10.18632/oncotarget.20317
Diagnostic accuracy of BRCA1–associated protein 1 in malignant mesothelioma: a meta-analysis
Liming Wang (2017)
10.1016/j.fsi.2019.07.009
Differential expression of immune-related genes in head kidney and spleen of cobia (Rachycentron canadum) having Streptococcus dysgalactiae infection.
S. Maekawa (2019)
10.1038/s41379-019-0309-6
Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma
Y. Kinoshita (2019)
10.1111/pin.12862
Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations
S. Matsumoto (2019)
10.1002/cncy.21928
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma
Y. Kinoshita (2018)
10.1016/j.jtho.2019.06.020
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
Pathology International
S. Noriki (2019)
10.1016/J.BULCAN.2017.11.007
Hétérogénéité moléculaire des mésothéliomes pleuraux malins
R. Tranchant (2017)
10.1007/978-981-10-8144-6_12
Pulmonary Malignancies (2): Mesothelioma—What Are the Roles of Genetic Factors in the Pathogenesis of Mesothelioma?
T. Nakano (2018)
10.1038/s41379-019-0371-0
Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma
S. Brich (2019)
Caracterización molecular de los carcinosarcomas de endometrio.
M. Biscuola (2018)
10.1016/j.lungcan.2018.09.019
A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Y. Kinoshita (2018)
Semantic Scholar Logo Some data provided by SemanticScholar